Q3 Report and presentation

Tromsø, Norway, 28th October 2021 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 25.6 million (19.5) and an EBITDA of NOK 9.0 million (7.1) for the third quarter of 2021. Highlights from Q3 2021 ArcticZymes Technologies (AZT) had Q3 sales of NOK 25.6 million – an increase of 31% (Q3 2020: NOK 19.5 million) Coronavirus-related sales are estimated at …

ArcticZymes Technologies – Share capital increase registered

Tromsø, 21 June 2021) Reference is made to the Annual General Meeting resolution on 20th May 2021, regarding share capital increase of 1,836,717 new shares by contribution in kind. The share capital increase pertaining to the issuance of the new shares under the contribution in kind has now been registered with the Norwegian Register of Business Enterprises. ArcticZymes Technologies’ new …

ArcticZymes Technologies divests Biotec BetaGlucans subsidiary to Lallemand

Tromsø, Norway, 14. December 2020. ArcticZymes Technologies ASA (AZT) has today entered into a Share Purchase Agreement (SPA) with Lallemand Inc’s subsidiary, Danstar Ferment AG for the divestment of AZT’s Biotec BetaGlucans AS subsidiary (BBG) The transaction is based on an Enterprise Value of NOK 70 Million payable in cash at closing – expected end of December 2020 and which …